Pfizer (PFE) is gearing up to release its earnings on April 29th, just before the market opens. As one of the most influential players in the global healthcare landscape, the company’s performance is always under scrutiny, and personally, I’m excited to see what numbers they bring to the table. But this is just my personal opinion, and I’m feeling optimistic about Pfizer's future. Looking at the stock’s 52-week range, which has fluctuated between $20.92 and $31.54, Pfizer’s current price of around $23 is well off its high. While this might seem like a setback, it could actually present a golden opportunity for investors seeking value. The company has been through some ups and downs, but it remains a formidable force in the pharmaceutical world—especially after its ground-breaking collabora